Resolving legal, ethical, and human rights challenges in HIV vaccine research.
In the absence of a cure for AIDS, attention has turned to the possibility of developing a preventive vaccine for HIV infection. Yet many scientific, ethical, legal, and economic obstacles remain. At the current rate, the development and production of an effective vaccine could take 15 to 20 years or longer. If tens of millions more HIV infections and deaths are to be avoided in the coming decades, vaccine research needs to be greatly expedited. Furthermore, it must be undertaken ethically, and the products of this research must benefit people in developing countries. This article, an edited and updated version of a paper presented at "Putting Third First," addresses challenges arising in HIV preventive vaccine research in developing countries. It does not address clinical research in developing countries relating to treatments or therapeutic vaccines. Nor does it address legal and ethical issues relating to HIV vaccine research in industrialized countries, although similar issues arise in both contexts. The article concludes that while ethical codes are silent on the obligation to undertake research and development, international law provides strong legal obligations--particularly with regard to industrialized states--that should be invoked to accelerate HIV vaccine development, and distribution.
Patterson
D
D
david.patterson@attglobal.net
D016915:AIDS Vaccines; D003906:Developing Countries; D004992:Ethics, Medical; D005260:Female; D015658:HIV Infections / Q000517:prevention & control*; D006297:Health Services Accessibility; D006806:Human Rights; D006801:Humans; D007258:Informed Consent; D008297:Male; D012106:Research / Q000331:legislation & jurisprudence
D016915:AIDS Vaccines